Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial

被引：3
|
作者：
Sugarman, Jeremy [1 ,2 ]
Donnell, Deborah J. [3 ]
Hanscom, Brett [3 ]
McCauley, Marybeth [4 ]
Grinsztejn, Beatriz [5 ]
Landovitz, Raphael J. [6 ]
机构：
[1] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
[3] Fred Hutchison Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA USA
[4] HIV Prevent Trials Network Leadership & Operat Ct, Washington, DC USA
[5] Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil
[6] UCLA, Ctr Clin AIDS Res & Educ, Los Angeles, CA USA
来源：
LANCET HIV | 2021年 / 8卷 / 11期
基金：
美国国家卫生研究院;
关键词：
PROTECTS MACAQUES; CABOTEGRAVIR;
D O I：
10.1016/S2352-3018(21)00153-3
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Two multinational clinical trials have shown safety and efficacy of long-acting injectable cabotegravir for HIV preexposure prophylaxis (PrEP). These results will alter the landscape of HIV prevention and related research. Nevertheless, designing and conducting this research involved several ethical issues. This Viewpoint describes how we managed ethical issues over the duration of one of these trials (HPTN 083). Specifically, we discuss the rationale for pursuing a long-acting injectable agent in the presence of effective oral PrEP, trial design choices, site selection and local standards of prevention, data monitoring and early stopping, effects of the COVID-19 pandemic, post-trial access, and assessment of long-term safety.
引用
收藏
页码：E723 / E728
页数：6
相关论文
共 50 条
  • [21] Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis
    Glidden, David V.
    CURRENT OPINION IN HIV AND AIDS, 2020, 15 (01) : 56 - 60
  • [22] Conjoint Analysis of User Acceptability of Sustained Long-Acting Pre-Exposure Prophylaxis for HIV
    Schieffer, Robert J.
    Bryndza Tfaily, Ewa
    D'Aquila, Richard
    Greene, George J.
    Carballo-Dieguez, Alex
    Giguere, Rebecca
    Tagliaferri Rael, Christine
    Kiser, Patrick F.
    Hope, Thomas J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2022, 38 (04) : 336 - 345
  • [23] The relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis: a modelled economic evaluation and threshold analysis in South Africa based on the HPTN 083 and 084 trials
    Jamieson, L.
    Johnson, L. F.
    Nichols, B. E.
    Delany-Moretlwe, S.
    Hosseinipour, M. C.
    Russell, C.
    Meyer-Rath, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 50 - 50
  • [24] Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada
    Adelakun, Adenike
    Dolph, Michael
    Matthews, Emily
    Oglesby, Alan
    Campbell, Kelly
    Davis, Ashley
    Xu, Janine
    Hardy, Isabelle
    Danchenko, Natalya
    Anderson, Sarah-Jane
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 234 - 235
  • [25] Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa
    Chih-Yuan Cheng
    Matthew Quaife
    Robyn Eakle
    Maria A. Cabrera Escobar
    Peter Vickerman
    Fern Terris-Prestholt
    BMC Public Health, 19
  • [26] Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa
    Cheng, Chih-Yuan
    Quaife, Matthew
    Eakle, Robyn
    Escobar, Maria A. Cabrera
    Vickerman, Peter
    Terris-Prestholt, Fern
    BMC PUBLIC HEALTH, 2019, 19 (1) : 996
  • [27] Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs
    Roth, Alexis M.
    Bartholomew, Tyler S.
    Ward, Kathleen M.
    Groves, Allison
    Mazzella, Silvana
    Bellamy, Scarlett
    Amico, K. Rivet
    Carrico, Adam W.
    Ironson, Gail
    Krakower, Douglas
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [28] Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women
    Bekker, L. G.
    Li, S.
    Pathak, S.
    Tolley, E. E.
    Marzinke, M. A.
    Justman, J. E.
    Mgodi, N. M.
    Chirenje, M.
    Swaminathan, S.
    Adeyeye, A.
    Farrior, J.
    Hendrix, C. W.
    Piwowar-Manning, E.
    Richardson, P.
    Eshelman, S. H.
    Redinger, H.
    Williams, P.
    Sista, N. D.
    ECLINICALMEDICINE, 2020, 21
  • [29] Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
    Anita J. Brogan
    Ashley E. Davis
    Claire E. Mellott
    Jeremy Fraysse
    Aimee A. Metzner
    Alan K. Oglesby
    PharmacoEconomics, 2024, 42 : 447 - 461
  • [30] Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
    Brogan, Anita J.
    Davis, Ashley E.
    Mellott, Claire E.
    Fraysse, Jeremy
    Metzner, Aimee A.
    Oglesby, Alan K.
    PHARMACOECONOMICS, 2024, 42 (04) : 447 - 461
12345